Advances and Challenges in Treating Melanoma with Immunotherapy: Patient Management in the Era of COVID-19

Released On
September 30, 2020

Expires On
September 30, 2021

Media Type

Completion Time
60 minutes



Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and Catamount Medical Education.

This activity is supported by an independent educational grant from Bristol Myers Squibb.

Credit Available

  • Physicians — maximum of 1.00 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, dermatologists, nurse practitioners, PAs, nurses, and other healthcare professionals who manage patients with melanoma.

Program Overview

A timely discussion with two distinguished faculty on advances in the treatment of melanoma with immunotherapy, management considerations regarding COVID-19 and the appropriate use of telemedicine.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply evidence to support appropriate use of immunotherapy in the treatment of melanoma
  • Discuss the identification and management of immune-related adverse events (irAEs) associated with immunotherapy for melanoma
  • Discuss available guidance for treating melanoma patients with immunotherapy in the era of COVID-19
  • Employ best practices for implementation of telemedicine in melanoma management


Jeffrey S. Weber, MD, PhD

Deputy Director, Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Grossman School of Medicine

Krista M. Rubin, MS, FNP-BC

Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital Cancer Center

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Catamount Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Jeffrey S. Weber, MD, PhD

  • Receipt of Intellectual Property Rights/Patent Holder: Biodesix, Moffitt Cancer Center
  • Consulting Fees: AstraZeneca, Biond, BMS, Celldex, CytomX, Genentech, GSK, Incyte, Merck, Novartis, Pfizer, Regeneron

Krista M. Rubin, RN, MS, FNP-BC

  • Consulting Fees: BMS, Merck

Planners and Managers
The PIM planners and managers have nothing to disclose. The Catamount Medical Education planners and managers have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. Participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgement for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be emailed.

Hardware and Software Requirements

CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information

For CME questions, please contact: Postgraduate Institute for Medicine at: